Latest filingSep 03, 2026Most recent Form 4
ASND
Ascendis Pharma A/S
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$49.2M2 buys
Total selling$6.23M1 sells
Net open-market+$43.0M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period3transactions
- P · Open-market buys · dominant2 · 67%
- S · Open-market sells1 · 33%
Activity by reported role
A joint filing can contribute to multiple roles3transactions
- Director · dominant3 · 100%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (1)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeBienaime Jean JacquesOrdinary Shares · Direct
2,900Aug 14, 2026
Holtug LarsOrdinary Shares · Direct
4,000Sep 02, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- BJ+$492.7k
- HL-$62.3k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
ASND transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ASND | HOLTUG LARS | DIR | sale | 236 | -$6.23M | S | — | 0.0% | 09/03 | 09/02 |
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 900 | $22.2M | P | +0.2% | 08/19 | 08/14 | |
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 1.10k | $27.0M | P | +0.2% | 08/19 | 08/14 |
Ascendis Pharma A/S Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Ascendis Pharma A/S?
HOLTUG LARS, BIENAIME JEAN JACQUES.
When was the latest reported open-market purchase?
Bienaime Jean Jacques reported a buy on Aug 14, 2026 valued at $22.2M. Read the SEC filing.
When was the latest reported open-market sale?
Holtug Lars reported a sale on Sep 02, 2026 valued at $6.23M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $430,319.41. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.